Enovis: Valuation Is Too Low, But Needs To Differentiate On Growth

Enovis continues to struggle in the market, as institutional investors just aren't interested in mid-single-digit growth from a mid-cap name. Management has guided for up to low-double-digit Recon growth in 2026, but overall growth, margin leverage, and meaningful free cash flow generation remain key hurdles for rerating. Bringing successful products over from Europe could drive more growth in hips and shoulders, but it will take time and clinical trials to get them to the market.

Seeking Alpha • Feb 12, 2026

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, UT. About Enovis Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life.

GlobeNewsWire • Feb 3, 2026

Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th

Dallas, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2025 financial results on Thursday, February 26th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com.

GlobeNewsWire • Jan 23, 2026

Top 3 Health Care Stocks That Could Blast Off This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga • Jan 21, 2026

Enovis Corporation (ENOV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Enovis Corporation (ENOV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m.

GlobeNewsWire • Jan 8, 2026

Enovis Appoints Oliver Engert as Chief Administrative Officer

Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative Officer, effective today.

GlobeNewsWire • Jan 5, 2026

An Enovis (ENOV) Insider Bets Big on the Stock With a Purchase of 2,468 Shares

John Kleckner reported an open market purchase of Enovis Corporation shares on Nov. 25, 2025. Kleckner is the principal accounting officer at Enovis Corporation.

The Motley Fool • Dec 8, 2025

Enovis Corporation (ENOV) Presents at UBS Global Healthcare Conference 2025 Transcript

Enovis Corporation ( ENOV ) UBS Global Healthcare Conference 2025 November 10, 2025 2:45 PM EST Company Participants Damien McDonald - CEO & Director Phillip Berry - Senior VP & CFO Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division All right. Good afternoon, everyone.

Seeking Alpha • Nov 10, 2025

Enovis Corporation (ENOV) Q3 2025 Earnings Call Transcript

Enovis Corporation ( ENOV ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Kyle Rose - Vice President of Investor Relations Damien McDonald - CEO & Director Phillip Berry - Senior VP & CFO Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Young Li - Jefferies LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Michael Matson - Needham & Company, LLC, Research Division Russell Yuen - William Blair & Company L.L.C., Research Division Danielle Antalffy - UBS Investment Bank, Research Division Dane Reinhardt - Robert W.

Seeking Alpha • Nov 7, 2025